13F Holdings
中文EN

TVGN Tevogen Inc.

Biological Products, (No Diagnostic Substances) · Nasdaq · SEC CIK 1860871 · Fiscal year ends 12/31

Financial factors as of 2026-09-30 (2026Q3), TTM = sum of the last four quarters

Growth

TTM revenue YoY—
TTM net income YoY26.3%
TTM EPS YoY23.9%
Revenue 3-yr CAGR—
Net income 3-yr CAGR—

Margins

Gross margin—
Operating margin—
Net margin—
FCF margin—
EBITDA margin—

Returns

ROE—
ROA-571.7%
ROIC (approx.)—
Asset turnover—

Leverage & solvency

Liabilities / assets421.4%
Debt / equity—
Current ratio0.13x
Interest coverage—

Cash quality & payout

Operating cash flow / net income0.43x
Accruals ratio-325.0%
Payout ratio—
Capex / revenue—

Factor history charts and full statement history on Pro 🔒

Financial statements

Line item FY20252025-12-31FY20242024-12-31FY20232023-12-31FY20222022-12-31
Income statement
Revenue————
R&D expense$11.11M$31.03M$4.40M—
SG&A expense$15.03M$22.53M$4.44M$953,083
Operating income-$26.14M-$53.56M-$8.84M—
Interest expense—$184,037$1.21M—
Income tax$4,750$1,750——
Net income-$26.28M-$13.73M-$60.48M$4.41M
EBITDA-$25.95M-$53.40M-$8.68M—
EPS (basic)-8.08-3.50-2.44—
EPS (diluted)-8.08-3.50-2.44—
Weighted avg. shares (diluted)3.32M2.93M24.75M—
Banking
Net interest income-$195,618-$184,037——
Balance sheet
Cash & equivalents$552,372$1.28M$1.05M$5.48M
Current assets$1.54M$2.36M$1.72M$274,356
PP&E, net$170,308$296,442$458,651—
Total assets$4.38M$3.46M$5.51M$357.14M
Current liabilities$7.07M$9.04M$85.48M$350,454
Short-term debt———$0
Total liabilities$12.62M$10.14M$99.93M$15.06M
Shareholders' equity-$8.23M-$6.67M-$94.43M-$33.95M
Shares outstanding4.02M3.56M120.00M2.38M
Cash flow statement
Operating cash flow-$12.33M-$12.00M-$8.17M-$215,395
Capital expenditure$64,439—$133,000—
Free cash flow-$12.39M—-$8.30M—
Investing cash flow-$64,439—-$133,000—
Financing cash flow$11.66M$12.23M$3.87M—
Depreciation & amortization$190,573$162,209$163,300—
Stock-based compensation$16.22M$40.76M——
Share buybacks——$342.98M—

· This company does not report gross profit in XBRL.

· No price-based ratios such as P/E or P/B (the site uses no licensed market data). Blanks are shown as —.

Source: SEC EDGAR XBRL (financial statements filed with the SEC), updated 2026-11-18 06:30.